CJC-1295 + Ipamorelin research overview

Compound identity and classification

CJC-1295 + Ipamorelin is classified as: Co-formulated GHRH analogue and selective ghrelin receptor agonist.

This material is a co-formulation of two distinct compounds: CJC-1295 without DAC, a modified GHRH(1-29) analogue, and Ipamorelin, a pentapeptide ghrelin receptor agonist. It is not a single molecule, and identity and purity are documented for each constituent separately rather than as a combined figure.

General research background

Combination secretagogue preparations appear in laboratory research because the two constituents act at different receptors. Published work on each constituent is preclinical; literature specific to the combined preparation is limited, and no combined potency claim should be inferred.

Molecular and biological pathways under investigation

Two pathways are under investigation in parallel: GHRH receptor activation with cAMP/PKA signaling, and growth hormone secretagogue receptor (GHS-R1a) activation with Gq/phospholipase C signaling in somatotroph models.

Areas of laboratory research

Reported laboratory work with this material clusters into the following areas. Listing an area describes where research activity exists, not an established result.

• Dual-receptor stimulation models in pituitary cell culture
• Constituent-specific analytical identity and purity verification
• Comparative signaling studies of GHRH versus ghrelin receptor agonism
• Formulation stability of co-lyophilized peptide mixtures

Analytical documentation

ATMI Labs publishes the identity and purity documentation supplied for each released lot. Any purity figure shown comes from the report filed for that specific batch rather than from a general catalog claim.

Research limitations

Published work involving CJC-1295 + Ipamorelin is largely confined to in vitro systems and preclinical animal models. Findings in those systems do not establish effects in humans, and model-to-model variability in preparation, vehicle, and endpoint selection limits direct comparison between studies.

Analytical purity describes the material, not biological activity. Laboratories should design their own controls, and treat any pathway description as a hypothesis under investigation rather than an established result.

Handling and laboratory considerations

Lyophilized research materials are handled as temperature-sensitive laboratory chemicals. Storage temperature, reconstitution solvent, container choice, and stability windows are determined by the receiving laboratory's written protocol.

Every ATMI Labs lot is released with batch documentation so identity and purity figures used in a study can be traced back to the specific lot in hand.

• Confirm the lot identifier on the vial label against the published quality record.
• Record lot, strength, and receipt date in the laboratory inventory before use.
• Follow institutional handling, labeling, and disposal procedures for research chemicals.

References and scientific sources

ATMI Labs does not summarize or reinterpret individual studies on this page. Laboratories designing work with this material are expected to consult the primary literature directly.

• PubMed / MEDLINE (National Library of Medicine) for peer-reviewed primary literature.
• PubChem and ChEMBL for chemical identity, structure, and physicochemical records.
• UniProt for sequence and receptor/target annotation where a protein target applies.
• The lot-specific quality record published by ATMI Labs for analytical identity and purity.

Research use scope

CJC-1295 + Ipamorelin supplied by ATMI Labs is sold exclusively for laboratory research and analytical purposes. It is not a drug, supplement, cosmetic, or food, and it is not intended for human or veterinary use.

Nothing on this page describes therapeutic use, dosing, or clinical outcomes. Literature referenced in general terms describes laboratory and preclinical model systems only.